Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Br J Obstet Gynaecol ; 102 Suppl 12: 12-6, 1995 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-7577849

RESUMO

In a large, double-blind, multicentre study, 269 patients with confirmed endometriosis were randomly allocated to receive either danazol (200 mg twice daily; n = 137) or gestrinone (2.5 mg twice weekly; n = 132) for 6 months. The two groups were comparable in terms of the staging of endometriosis by the American Fertility Society (1979) score. After the sixth month of treatment, repeat laparoscopy was performed. Clinical assessment, haematological and biochemical investigations were carried out during the 6 months of treatment and for a further 12 months' follow-up and are compared between the two groups. A total of 15 patients from the gestrinone group, including four patients with hirsutism, and 17 patients from the danazol group, including six patients with headache, withdrew because of adverse symptoms. An additional 22 patients, including 10 from the gestrinone group and 12 from the danazol group withdrew because of lack of efficacy, pregnancy, elevated hepatic function tests or for reasons unrelated to the trial. Total American Fertility Society scoring showed an improvement of 73.3% in 101 patients receiving gestrinone and 72.7% in 99 patients receiving danazol. The results showed a significant reduction in the severity of dysmenorrhoea by the third month in the danazol group and at 6 months in both groups. There was a significant (P < 0.001) increase in weight observed in both groups during treatment. Overall, the tolerability of danazol and gestrinone was good; however, significantly more patients with gestrinone complained of hirsutism while significantly more with danazol complained of leg cramps. During the 12 months of follow-up, mild, moderate or severe degrees of lower abdominal pain, dysmenorrhoea and deep dyspareunia all fluctuated, with no statistically significant increase in frequency in either group.


Assuntos
Danazol/uso terapêutico , Endometriose/tratamento farmacológico , Gestrinone/uso terapêutico , Danazol/efeitos adversos , Método Duplo-Cego , Feminino , Gestrinone/efeitos adversos , Humanos
2.
Fertil Steril ; 53(1): 97-102, 1990 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-2403937

RESUMO

Our experience in 242 consecutive ultrasound directed follicle aspirations using the perurethral technique is reported. The mean number of follicles punctured per patient was 9.6 (range 20 to 35), resulting in a mean oocyte yield of 6.1 (range 0 to 31) per patient. It was necessary to change to another ultrasound directed route in 20 patients, and we failed to retrieve oocytes in a further 6 patients. There were no serious complications. The fertilization and cleavage rates were 68% and 91%, respectively. Embryo transfer was performed in 178 cases, resulting in 39 clinical pregnancies (21.9%). Ultrasound directed follicle aspiration by the perurethral route is an efficient way of collecting oocytes and is acceptable to patients. There is no need for general anaesthesia, so this technique is well suited to in vitro fertilization programs based on outpatient procedures.


Assuntos
Biópsia por Agulha/métodos , Oócitos/citologia , Ultrassonografia/métodos , Separação Celular/métodos , Feminino , Humanos , Ultrassonografia/efeitos adversos
3.
Br J Hosp Med ; 39(5): 440-5, 1988 May.
Artigo em Inglês | MEDLINE | ID: mdl-2968128

RESUMO

Endometriosis occupies a unique position in medicine. The natural history of the disease is uncertain, its precise aetiology is unknown, the clinical presentation is inconsistent, and the treatment is poorly standardized. This review attempts to draw some conclusions from the growing number of publications devoted to the subject, and to provide guidelines for patient management.


Assuntos
Endometriose , Neoplasias Pélvicas , Danazol/uso terapêutico , Diagnóstico Diferencial , Endometriose/diagnóstico , Endometriose/etiologia , Endometriose/terapia , Estrogênios/uso terapêutico , Feminino , Gestrinone/uso terapêutico , Hormônio Liberador de Gonadotropina/análogos & derivados , Humanos , Histerectomia , Infertilidade Feminina/etiologia , Laparoscopia , Terapia a Laser , Neoplasias Pélvicas/diagnóstico , Neoplasias Pélvicas/etiologia , Neoplasias Pélvicas/terapia , Progestinas/uso terapêutico
4.
Br Med J (Clin Res Ed) ; 293(6558): 1329-30, 1986 Nov 22.
Artigo em Inglês | MEDLINE | ID: mdl-3098339

RESUMO

Calcitonin gene related peptide is an extremely potent vasoactive peptide that causes profound vasodilatation in man. Its distribution in perivascular nerves suggests that one of its functions may be the regulation of peripheral vascular tone. Pregnancy is a physiological condition in which there are major haemodynamic changes. An increase in plasma volume of about 40% necessitates changes in peripheral vascular tone. In a cross sectional study plasma concentrations of immunoreactive calcitonin gene related peptide were measured throughout normal pregnancy and at five to seven days post partum. Calcitonin gene related peptide concentrations were significantly increased throughout pregnancy but fell after delivery. Calcitonin gene related peptide may participate in the physiological regulation of vasomotor tone in man.


Assuntos
Neuropeptídeos/sangue , Gravidez/sangue , Adolescente , Adulto , Peptídeo Relacionado com Gene de Calcitonina , Estudos Transversais , Feminino , Humanos , Período Pós-Parto/sangue
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...